• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

梗阻性肥厚型心肌病中的线粒体能量代谢与钙激活ATP酶

Mitochondrial Energetics and Ca2-Activated ATPase in Obstructive Hypertrophic Cardiomyopathy.

作者信息

Lombardi Maria, Lazzeroni Davide, Pisano Annalinda, Girolami Francesca, Alfieri Ottavio, La Canna Giovanni, d'Amati Giulia, Olivotto Iacopo, Rimoldi Ornella E, Foglieni Chiara, Camici Paolo G

机构信息

Cardiovascular Research Center, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy.

Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome and Policlinico Umberto I, 00161 Rome, Italy.

出版信息

J Clin Med. 2020 Jun 9;9(6):1799. doi: 10.3390/jcm9061799.

DOI:10.3390/jcm9061799
PMID:32527005
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7356244/
Abstract

Hypertrophic cardiomyopathy (HCM) is the most common genetic disease of the myocardium associated to mutations in sarcomeric genes, but the link between genotype and phenotype remains poorly understood. Magnetic resonance spectroscopy studies have demonstrated impaired cardiac energetics in patients with HCM, and altered mitochondria were described in biopsies, but little is known about possible perturbations of mitochondrial function and adenosine triphosphate (ATP) production/consumption. The aim of this study was to investigate possible abnormalities in mitochondrial enzymes generating/scavenging reactive oxygen species, and changes in the Ca-activated ATPases in myocardial tissue from patients with obstructive HCM undergoing surgical myectomy compared to unused donor hearts (CTRL). Methods and Results: Both the amount and activity of mitochondrial Complex I (nicotinamide adenine dinucleotide -reduced form, NADH, dehydrogenase) were upregulated in HCM vs. CTRL, whilst the activity of Complex V (ATP synthase) was not reduced and ATP levels were significantly higher in HCM vs. CTRL. Antioxidant Mn-activated superoxide dismutase (SOD2) and (m)-aconitase activities were increased in HCM vs. CTRL. The Cu/Zn-activated superoxide dismutase (SOD1) amount and mtDNA copy number were unaltered in HCM. Total Ca-activated ATPase activity and absolute amount were not different HCM vs. CTRL, but the ratio between ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting type 2 (ATP2A2) and type 1 (ATP2A1), ATP2A2/ATP2A1, was increased in HCM in favor of the slow isoform (ATP2A2). Conclusion: HCM is characterized by mitochondrial Complex I hyperactivity and preserved Caactivated ATPase activity with a partial switch towards slow ATP2A2. This data may give insight into the abnormal cellular energetics observed in HCM cardiomyopathy but other studies would need to be performed to confirm the observations described here.

摘要

肥厚型心肌病(HCM)是最常见的与肌节基因突变相关的心肌遗传性疾病,但基因型与表型之间的联系仍知之甚少。磁共振波谱研究表明,HCM患者存在心脏能量代谢受损,活检中也发现线粒体改变,但关于线粒体功能以及三磷酸腺苷(ATP)生成/消耗的可能扰动却知之甚少。本研究旨在调查梗阻性HCM患者接受外科心肌切除术时,其心肌组织中产生/清除活性氧的线粒体酶可能存在的异常,以及钙激活ATP酶的变化,并与未使用的供体心脏(对照组)进行比较。方法与结果:与对照组相比,HCM患者线粒体复合体I(烟酰胺腺嘌呤二核苷酸还原型,NADH,脱氢酶)的数量和活性均上调,而复合体V(ATP合酶)的活性未降低,且HCM患者的ATP水平显著高于对照组。与对照组相比,HCM患者抗氧化锰激活超氧化物歧化酶(SOD2)和(m)-乌头酸酶活性增加。HCM患者铜/锌激活超氧化物歧化酶(SOD1)的数量和线粒体DNA拷贝数未改变。HCM患者与对照组相比,总钙激活ATP酶活性和绝对量无差异,但HCM患者中ATP酶肌浆网/内质网钙转运2型(ATP2A2)与1型(ATP2A1)的比值增加,有利于慢异构体(ATP2A2)。结论:HCM的特征是线粒体复合体I活性亢进,钙激活ATP酶活性保留,且部分转向慢ATP2A2。这些数据可能有助于深入了解HCM心肌病中观察到的异常细胞能量代谢,但需要进行其他研究来证实此处描述的观察结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fc4/7356244/e721d7ec7eaa/jcm-09-01799-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fc4/7356244/9088f4e867ba/jcm-09-01799-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fc4/7356244/f6bb2d3f8b40/jcm-09-01799-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fc4/7356244/e721d7ec7eaa/jcm-09-01799-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fc4/7356244/9088f4e867ba/jcm-09-01799-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fc4/7356244/f6bb2d3f8b40/jcm-09-01799-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fc4/7356244/e721d7ec7eaa/jcm-09-01799-g003.jpg

相似文献

1
Mitochondrial Energetics and Ca2-Activated ATPase in Obstructive Hypertrophic Cardiomyopathy.梗阻性肥厚型心肌病中的线粒体能量代谢与钙激活ATP酶
J Clin Med. 2020 Jun 9;9(6):1799. doi: 10.3390/jcm9061799.
2
Altered Cardiac Energetics and Mitochondrial Dysfunction in Hypertrophic Cardiomyopathy.肥厚型心肌病中心脏能量代谢改变和线粒体功能障碍。
Circulation. 2021 Nov 23;144(21):1714-1731. doi: 10.1161/CIRCULATIONAHA.121.053575. Epub 2021 Oct 21.
3
Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration.人类肥厚型心肌病中线粒体功能障碍与心肌细胞结构破坏有关,并通过改善 NADH 驱动的线粒体呼吸得到纠正。
Eur Heart J. 2023 Apr 1;44(13):1170-1185. doi: 10.1093/eurheartj/ehad028.
4
Differences in microRNA-29 and Pro-fibrotic Gene Expression in Mouse and Human Hypertrophic Cardiomyopathy.小鼠和人类肥厚型心肌病中微小RNA-29与促纤维化基因表达的差异
Front Cardiovasc Med. 2019 Dec 17;6:170. doi: 10.3389/fcvm.2019.00170. eCollection 2019.
5
Defects in the Proteome and Metabolome in Human Hypertrophic Cardiomyopathy.人类肥厚型心肌病中蛋白质组和代谢组的缺陷。
Circ Heart Fail. 2022 Jun;15(6):e009521. doi: 10.1161/CIRCHEARTFAILURE.121.009521. Epub 2022 May 11.
6
ENerGetIcs in hypertrophic cardiomyopathy: traNslation between MRI, PET and cardiac myofilament function (ENGINE study).肥厚型心肌病中的能量代谢:MRI、PET 和心肌丝功能之间的转化(ENGINE 研究)。
Neth Heart J. 2013 Dec;21(12):567-71. doi: 10.1007/s12471-013-0478-8.
7
Surgical pathology of subaortic septal myectomy: histology skips over clinical diagnosis.主动脉瓣下间隔心肌切除术的外科病理学:组织学跳过临床诊断。
Cardiovasc Pathol. 2018 Mar-Apr;33:32-38. doi: 10.1016/j.carpath.2017.12.002. Epub 2018 Jan 3.
8
Myosins and MyomiR Network in Patients with Obstructive Hypertrophic Cardiomyopathy.梗阻性肥厚型心肌病患者中的肌球蛋白与肌微RNA网络
Biomedicines. 2022 Sep 3;10(9):2180. doi: 10.3390/biomedicines10092180.
9
Unchanged protein levels of SERCA II and phospholamban but reduced Ca2+ uptake and Ca(2+)-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts.与非心力衰竭患者相比,扩张型心肌病患者心肌肌浆网中SERCA II和受磷蛋白的蛋白质水平未变,但Ca2+摄取和Ca(2+)-ATP酶活性降低。
Circulation. 1995 Dec 1;92(11):3220-8. doi: 10.1161/01.cir.92.11.3220.
10
Altered adenosine triphosphatase activities in pigs with naturally occurring hypertrophic cardiomyopathy.
Vet Res Commun. 1995;19(2):115-25. doi: 10.1007/BF01839277.

引用本文的文献

1
Hepato-cardiac interorgan communication controls cardiac hypertrophy via combined endocrine-autocrine FGF21 signaling.肝心器官间通讯通过内分泌-自分泌联合的FGF21信号传导控制心脏肥大。
Cell Rep Med. 2025 Jun 17;6(6):102125. doi: 10.1016/j.xcrm.2025.102125. Epub 2025 May 7.
2
An Electromechanical Model-Based Study on the Dosage Effects of Ranolazine in Treating Failing HCM Cardiomyocyte.基于机电模型的雷诺嗪治疗失代偿肥厚型心肌病心肌细胞剂量效应研究
Cell Mol Bioeng. 2025 Feb 21;18(2):137-162. doi: 10.1007/s12195-025-00842-5. eCollection 2025 Apr.
3
Austrian consensus statement on the diagnosis and management of hypertrophic cardiomyopathy.

本文引用的文献

1
Hypertrophic Cardiomyopathy: Diverse Pathophysiology Revealed by Genetic Research, Toward Future Therapy.肥厚型心肌病:遗传学研究揭示的多种病理生理学机制,迈向未来的治疗方法。
Keio J Med. 2020 Dec 25;69(4):77-87. doi: 10.2302/kjm.2019-0012-OA. Epub 2020 Mar 28.
2
2018 ESC/ESH Guidelines for the management of arterial hypertension.2018年欧洲心脏病学会/欧洲高血压学会动脉高血压管理指南。
Eur Heart J. 2018 Sep 1;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339.
3
Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology.
奥地利肥厚型心肌病诊断与管理共识声明
Wien Klin Wochenschr. 2024 Oct;136(Suppl 15):571-597. doi: 10.1007/s00508-024-02442-1. Epub 2024 Oct 1.
4
Genetic Mutations and Mitochondrial Redox Signaling as Modulating Factors in Hypertrophic Cardiomyopathy: A Scoping Review.遗传突变与线粒体氧化还原信号在肥厚型心肌病中的调节作用:系统评价
Int J Mol Sci. 2024 May 28;25(11):5855. doi: 10.3390/ijms25115855.
5
Whole-Exome Sequencing Reveals Mutational Signature of Hypertrophic Cardiomyopathy.全外显子组测序揭示肥厚型心肌病的突变特征。
Int J Gen Med. 2023 Oct 11;16:4617-4628. doi: 10.2147/IJGM.S422598. eCollection 2023.
6
Myosins and MyomiR Network in Patients with Obstructive Hypertrophic Cardiomyopathy.梗阻性肥厚型心肌病患者中的肌球蛋白与肌微RNA网络
Biomedicines. 2022 Sep 3;10(9):2180. doi: 10.3390/biomedicines10092180.
7
Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update.抗糖尿病治疗、心力衰竭与氧化应激:最新进展
J Clin Med. 2022 Aug 9;11(16):4660. doi: 10.3390/jcm11164660.
肥厚型心肌病的代谢变化:欧洲心脏病学会心肌功能工作组的科学更新。
Cardiovasc Res. 2018 Aug 1;114(10):1273-1280. doi: 10.1093/cvr/cvy147.
4
Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy.肥厚型心肌病心力衰竭的临床特征及处理。
JACC Heart Fail. 2018 May;6(5):353-363. doi: 10.1016/j.jchf.2017.09.011. Epub 2018 Apr 11.
5
Allele-specific differences in transcriptome, miRNome, and mitochondrial function in two hypertrophic cardiomyopathy mouse models.两种肥厚型心肌病小鼠模型中转录组、miRNome 和线粒体功能的等位基因特异性差异。
JCI Insight. 2018 Mar 22;3(6):94493. doi: 10.1172/jci.insight.94493.
6
CardioClassifier: disease- and gene-specific computational decision support for clinical genome interpretation.CardioClassifier:针对临床基因组解读的疾病和基因特异性计算决策支持。
Genet Med. 2018 Oct;20(10):1246-1254. doi: 10.1038/gim.2017.258. Epub 2018 Jan 25.
7
Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.肥厚型心肌病:遗传学、发病机制、临床表现、诊断与治疗
Circ Res. 2017 Sep 15;121(7):749-770. doi: 10.1161/CIRCRESAHA.117.311059.
8
P2X7 receptor antagonism modulates IL-1β and MMP9 in human atherosclerotic vessels.P2X7 受体拮抗剂调节人动脉粥样硬化血管中的白细胞介素-1β和基质金属蛋白酶 9。
Sci Rep. 2017 Jul 7;7(1):4872. doi: 10.1038/s41598-017-05137-y.
9
InterVar: Clinical Interpretation of Genetic Variants by the 2015 ACMG-AMP Guidelines.InterVar:依据2015年美国医学遗传学与基因组学学会(ACMG)-分子病理学协会(AMP)指南对基因变异进行临床解读
Am J Hum Genet. 2017 Feb 2;100(2):267-280. doi: 10.1016/j.ajhg.2017.01.004. Epub 2017 Jan 26.
10
Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy.肥厚型心肌病中的心肌能量耗竭和动态收缩功能障碍。
Nat Rev Cardiol. 2016 Nov;13(11):677-687. doi: 10.1038/nrcardio.2016.98. Epub 2016 Jul 14.